TCGA-44-2656-01A-02R-A278-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.550
- INTERFERON_ALPHA_RESPONSE+0.430
- INTERFERON_GAMMA_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.380
- ALLOGRAFT_REJECTION+0.360
- UV_RESPONSE_DN+0.280
- INFLAMMATORY_RESPONSE+0.260
- KRAS_SIGNALING_UP+0.260
- COMPLEMENT+0.230
- PEROXISOME+0.180
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.430
- KRAS_SIGNALING_DN-0.340
- MYOGENESIS-0.330
- APICAL_JUNCTION-0.320
- MYC_TARGETS_V2-0.280
- ESTROGEN_RESPONSE_LATE-0.270
- HEDGEHOG_SIGNALING-0.270
- APICAL_SURFACE-0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- UV_RESPONSE_UP-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG628 | — | — | 0.862 |
| 2 | TCGA-44-3918-01A-01R-A278-07 | — | cohortMD2 | 0.843 |
| 3 | 90c9f8cd-4c8c-4f07-af2f-e17db69bd561 | — | — | 0.838 |
| 4 | 06d5607b-45d7-4247-8d42-709d9d292530 | — | — | 0.823 |
| 5 | MNG746 | — | — | 0.823 |
| 6 | SJEPD031138_D1.RNA-Seq | EPN | Supratentorial EPN | 0.792 |
| 7 | 82924 | EPN | Supratentorial EPN | 0.777 |
| 8 | cb6e4e0c-6f89-4ea5-a89d-1b0da8cf7fac | — | — | 0.768 |
| 9 | SRR2016949 | — | — | 0.766 |
| 10 | MNG733 | — | — | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.550 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.110 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |